SeLux’s Next-Generation Phenotyping (NGP) platform will enable physicians to transition patients to personalized antibiotic therapies much more quickly – from one to four days earlier – than current state-of-the-art platforms, providing next-day personalized therapies for nearly all patients.
SeLux NGP detects antibiotic effects on bacteria more rapidly and at lower concentrations than currently possible. This enables bacterial susceptibilities to different antibiotics to be determined virtually simultaneously to the identification of the infecting bacteria.
SeLux’s second-generation platform will deliver same-day personalized therapy results for patients with bacteremia, septicemia, and urinary tract infections. The platform obviates the need for traditional blood and agar cultures by utilizing SeLux NGP’s speed and accuracy.
SeLux’s technology works across a vast menu of bacteria and fungi, delivering an unmatched breadth of AST results to labs. The initial product will focus on the major non-fastidious bacterial pathogens and later upgrades will add fastidious bacteria and fungi.
SeLux NGP provides a menu of 50+ antibiotics per sample -- 5X more antibiotics than current AST technology -- and, due to its ready expansion room, will seamlessly incorporate newly-approved drugs.
Since effective antibiotic stewardship requires all patients to be rapidly transitioned to targeted therapies, SeLux’s first product is designed to provide rapid results from isolates deriving from all sample types.
SeLux NGP leverages standard microbiology processes so it can easily integrate into clinical microbiology laboratories to rapidly improve antibiotic susceptibility testing efficiencies and speed.
One SeLux system will deliver over 100 AST tests per day, matching standard laboratory susceptibility exceeding the workflow needs of labs.
Designed for frictionless integration in existing labs, SeLux’s breakthrough technology promises superior return on investment to health systems by reducing pharmacy costs, patient length of stay, Hospital Acquired Conditions (HAC), and HAC reduction penalties.
CTO & Co-founder
Aleksandar Vacic is the President and co-founder of SeLux. His primary leadership role at SeLux is engineering and product development. As an applied physicist and electrical engineer, Alek believes that both strong theoretical foundations and hands-on practical insights must be exploited to commercialize novel technologies. He enjoys working with multidisciplinary teams solving complex problems. His work has spanned semiconductors, plasma engineering, optics, optoelectronics, bioelectronics, Monte Carlo simulations, and numerical algorithms.
Previously, he led the Cell Processing team at 1366 Technologies where he transferred processes to customer manufacturing sites in Asia and Europe, and developed a plasma texturing process for high efficiency solar cells.
While at Yale he developed fabrication and design methods to improve yield and reliability of nanoscale biosensors including the understanding of semiconductor-biomolecule interaction which resulted in a novel calibration and quantification methodology. He has 2 granted, 1 licensed, and 10 pending patents and provisional applications. He earned his PhD from Yale and Dipl.-Ing. (5 year) in Technical Physics from the School of Electrical Engineering in Belgrade (Serbia) as Valedictorian (Class of 600+). While at Yale he was awarded the Best Presentation award at the Nanodevices for Defense and Security Conference 2009 and Yale College Prize Teaching Fellowship. When not solving difficult problems, Alek enjoys travelling, cooking and running with his awesome spouse, Yi-Wen.
President & Co-founder
As the Principal Software Developer, Derek is responsible for the design and implementation of the software architecture for the SeLux Diagnostics AST platform. <\P>
Derek has over 20 years of experience in the medical imaging, biotech, and immunotherapy industries. Prior to joining SeLux Diagnostics, he was Principal Software Developer at the Waltham site for Juno Therapeutics, a Seattle-based immunotherapy company. At Juno, he built a suite of data storage, processing, and analysis tools to enable identification of lead candidates in the Juno antibody discovery platform. Previously, Derek was Director of Software Engineering at SRU Biosystems, where he developed data acquisition and analysis capabilities for their label-free detection platform for small molecule and protein binding assays. He began his career with Picker Medical Systems (now Philips Healthcare), working on visualization of dose distributions for their AcQSim™ radiation therapy treatment planning software.
Principal Software Engineer
Senior Software Engineer
SeLux’s interdisciplinary team has expertise in microbiology, biochemistry, chemistry, engineering, software, and algorithm design and is buttressed by distinguished experts in Clinical Microbiology, Infectious Disease, and Machine Learning. We are always looking for innovative scientific, engineering, marketing, and business development talent.
SeLux Diagnostics, Inc
56 Roland Street, Suite 206
Charlestown, MA 02129
Info [AT] SeLuxDX [.] com